Skip to Main Content

Paper Details

Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.
Cell Rep Med
22
2022
LUAD, RNA, TP53, co-measured genes, expression, immune cell, lung adenocarcinoma, lung adenocarcinoma (LUAD) tumors, patient, reverse, somatic genome, structurally, tumor
Author NameAffiliation
Jianfang LiuChan Soon-Shiong Institute of Molecular Medicine at Windber
Clifton L DalgardUniformed Services University of the Health Sciences
Stella SomiariChan Soon-Shiong Institute of Molecular Medicine at Windber
Clesson TurnerJohn P. Murtha Cancer Center Research Program, Uniformed Services University
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Thomas P ConradsWomen's Health Integrated Research Center, USA Gynecologic Cancer Center of Excellence, Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences
Hai HuChan Soon-Shiong Institute of Molecular Medicine at Windber, USA John P. Murtha Cancer Center Research Program, Uniformed Services University
Craig D ShriverJohn P. Murtha Cancer Center Research Program, Uniformed Services University
  • 1 - 9

Datasets

Release 1.2